ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

ACLU Sues Myriad, U.S. Patent Office Over Patents For BRCA Gene Mutations

May 15, 2009

In Brief: FDA Changes Package Inserts For Thiotepa, Cyclophosphamide, As Committee Suggested

August 31, 1979

“Honor Roll” Of Top Investigators Who Won’t Be Funded Because Of Cuts

March 8, 1985

Advanced Radiation Technique Reduced Swallowing Problems

May 28, 2010

Center Core Grants Picture Less Bleak; Competing Renewals To Receive 50% Of Recommended Increases

January 4, 1980